|
Video: What is a Stock Split?
|
|
Kronos Bio is a late-stage clinical development biopharmaceutical company, with a focus on developing therapeutics that target the dysregulated transcription that causes cancer and other serious diseases. Co.'s primary product candidate, entospletinib, is an orally administered, selective spleen tyrosine kinase (SYK) inhibitor. Co. is also developing lanraplenib, its orally-administered SYK inhibitor. In addition, Co. is developing KB-0742, its internally discovered, oral cyclin dependent kinase 9 inhibitor, for the treatment of MYC-amplified and other transcriptionally addicted solid tumors. According to our Kronos Bio stock split history records, Kronos Bio has had 4 splits. | |
|
Kronos Bio (KRON) has 4 splits in our Kronos Bio stock split history database. The first split for KRON took place on January 30, 1996. This was a 3 for 2
split, meaning for each 2
shares of KRON owned pre-split, the shareholder now owned 3 shares. For example, a 1000 share position pre-split, became a 1500 share position following the split. KRON's second split took place on March 10, 1999. This was a 3 for 2
split, meaning for each 2
shares of KRON owned pre-split, the shareholder now owned 3 shares. For example, a 1500 share position pre-split, became a 2250 share position following the split. KRON's third split took place on November 16, 2001. This was a 3 for 2 split, meaning for each 2 shares of KRON owned pre-split, the shareholder now owned 3 shares. For example, a 2250 share position pre-split, became a 3375 share position following the split. KRON's 4th split took place on November 03, 2003. This was a 3 for 2 split, meaning for each 2 shares of KRON owned pre-split, the shareholder now owned 3 shares. For example, a 3375 share position pre-split, became a 5062.5 share position following the split.
When a company such as Kronos Bio splits its shares, the market capitalization before and after the split takes place remains stable, meaning the shareholder now owns more shares but each are valued at a lower price per share. Often, however, a lower priced stock on a per-share basis can attract a wider range of buyers. If that increased demand causes the share price to appreciate, then the total market capitalization rises post-split. This does not always happen, however, often depending on the underlying fundamentals of the business.
Looking at the Kronos Bio stock split history from start to finish, an original position size of 1000 shares would have turned into 5062.5 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Kronos Bio shares, starting with a $10,000 purchase of KRON, presented on a split-history-adjusted basis factoring in the complete Kronos Bio stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
10/12/2020 |
|
End date: |
04/25/2024 |
|
Start price/share: |
$29.00 |
|
End price/share: |
$0.98 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-96.62% |
|
Average Annual Total Return: |
-61.62% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$338.05 |
|
Years: |
3.54 |
|
|
|
Date |
Ratio |
01/30/1996 | 3 for 2
| 03/10/1999 | 3 for 2
| 11/16/2001 | 3 for 2 | 11/03/2003 | 3 for 2 |
|
|